Clinical features of abnormal α-fetoprotein in 15 patients with chronic viral hepatitis B after treatment with antiviral drugs

Table 1 Baseline clinical data of 15 patients with chronic hepatitis B combined with elevated -fetoprotein

No.	Sex	Age	ALT	AST	TBIL	ALP	GGT	TBA	ALB	AFP	ANA	IgG	HBV-DNA
1	Female	62	29.9	41.3	8.9	98.9	281.7	24.5	41.4	29.77	1: 320	18.73	30.8
2	Male	48	61.9	100.3	27	114.4	57.5	82.6	27.9	32.96	-	30	-1
3	Male	56	35.7	44	58.6	140.9	106.8	78.3	27.9	19.36	-	25.1	-1
4	Female	64	77	69.7	24.3	143.7	100.1	67.9	25.9	142.96	-	34.7	6.49 × 103
5	Male	57	34.5	50.3	46.5	92	93.3	299.5	29.8	85.75	-	26	-1
6	Female	57	28.5	65	44.5	149.9	185.8	45.6	25	77.42	1: 160	21.15	1.27 × 102
7	Male	67	15.5	21.8	18.8	71.8	48	34.8	34	8.47	<1: 80	21.8	-1
8	Male	57	22.7	57.2	20.1	107.7	46.2	39.7	33	42.99	<1: 80	28.03	5.48 × 102
9	Male	60	34.3	66	45.8	157.8	92	60.9	24.1	18.56	-	22.32	-1
10	Female	69	20.6	27	12.6	178.5	41	2	22.3	14.28	<1: 80	25.23	-1
11	Female	51	39.5	35	17.2	73.1	51	33.5	40.3	6.85	<1: 80	20.27	3.06 × 102
12	Male	49	24.7	30	33.1	111.1	134	3.8	28.8	340.1	<1: 80	19.89	51.5
13	Male	52	36.4	104	50.5	148.8	179	12.5	36.9	1004	<1: 80	24.48	5.24 × 103
14	Male	57	72.6	63	8.1	59.1	48	70.8	40.5	158.3	<1: 80	22.04	-1
15	Male	50	24	32	30.3	123.7	65	8	35.1	10.69	<1: 80	25.27	-1

¹Hepatitis B virus DNA level below lower limit of detection.

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; ALP: Alkaline phosphatase; GGT: Gamma-glutamyltransferase; TBA: Total bile acid; ALB: Albumin; AFP: Alpha fetoprotein; ANA: Antinuclear antibody; HBV-DNA: Hepatitis B virus DNA.

Table 2 Pathological features of 15 patients with chronic hepatitis B combined with elevated alpha fetoprotein

No.	II	Lym/PCs I	FN	BN	FDL	LI	PI	BDI	ABD	Fibrosis	Ishak score	G	S
1	3	Yes	2	0	1	4	3	0	0	3	12	G3	S1
2	3	Yes	6	1	1	2	3	0	0	6	15	G3-4	S4
3	4	Yes	5	1	1	2	3	0	0	6	15	G3-4	S4
4	4	Yes	5	1	1	3	4	0	0	5	17	G3-4	S3-4
5	4	Yes	5	1	1	3	3	0	0	5	16	G2-3	S4
6	4	Yes	5	1	1	4	4	0	0	5	18	G4	S3-4
7	4	No	4	1	1	2	4	0	0	6	15	G2-3	S4
8	4	Yes	6	1	1	3	3	0	0	6	17	G4	S4
9	4	Yes	4	1	1	3	3	1	0	6	15	G3-4	S4
10	3	Yes	4	1	1	4	3	1	0	3	15	G3-4	S3-4
11	3	Yes	6	1	1	3	4	1	0	6	17	G3	S4
12	4	Yes	4	1	1	3	4	1	0	6	16	G4	S4
13	4	Yes	5	1	1	3	4	0	0	6	17	G3	S3-4
14	3	Yes	1	0	1	2	2	0	0	3	8	G3	S3-4
15	2	Yes	0	0	0	1	2	0	0	3	5	G2	S3-4

II: Interfacial inflammation; Lym/PCs I: Infiltration of lymphoid/plasma cells; FN: Fusion necrosis; BN: Bridging necrosis; FDL: Florid duct lesion; LI: Lobular inflammation; PI: Portal inflammation; BDI: Bile ductal injure; ABD: Absence of bile duct.

Table 3 Autoimmune hepatitis diagnostic scores of 15 patients

No.	Integrated diagnostic score		Simplified diagnostic score
	Pre-treatment	Post-treatment
1	13	15	6
2	9	11	4
3	9	11	4
4	12	14	4
5	9	11	4
6	10	12	6
7	9	11	4
8	9	11	4
9	8	10	4
10	9	11	4
11	10	12	4
12	8	10	4
13	9	11	4
14	8	10	4
15	9	11	4

Table 4 Changes in -fetoprotein before and after hormone therapy

Parameters	Pre-hormone therapy	1 months after hormone therapy	2-3 months after hormone therapy	Z/t	P value
AFP (μg/L)	32.96 (12.49-114.36)	15.38 (11.21-41.71)	5.2 (3.94, 9.44)1	3.18	0.001

¹Using single-factor repeated measures one-way analysis of variance, the difference in alpha fetoprotein index between 2 and 3 months after hormone therapy and before treatment was significant.

AFP: Alpha fetoprotein.

Table 5 Biochemical index changes before and after hormone therapy, n (%)/mean ± SD

Parameters	Pre-hormone therapy	2-3 months after hormone therapy	Z/t	P value
IgG	24.83 ± 4.32	16.09 ± 2.87	16.263	< 0.001
ALT	41 (33.85-255.5)	34.7 (28.5-39.5)	1.153	0.249
AST	51 (39-221)	33 (27.5-43)	2.274	0.023
TBIL	24.3 (14.9-45.5)	18.5 (13.15-46.25)	0.454	0.65
ALP	115.58 ± 35.99	82.72 ± 28.13	4.035	0.002
GGT	100.26 ± 72.99	63.22 ± 24.96	1.591	0.138
TBA	39.7 (18.5-74.55)	49.2 (12.95-90.15)	0.874	0.382
ALB	32.31 ± 6.36	36.18 ± 4.57	2.983	0.011

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; ALP: Alkaline phosphatase; GGT: Gamma-glutamyltransferase; TBA: Total bile acid; ALB: Albumin.